RenovaroCube acquires 100% ownership of Cyclomics for advanced cancer diagnostics.
RenovaroCube acquires 100% ownership of Cyclomics, strengthening their partnership in advanced cancer diagnostics. The acquisition further cements their commitment to cutting-edge technologies in cancer diagnostics and treatment. This partnership leverages relationships with Oxford Nanopore and Nvidia to position RenovaroCube as a leader in early cancer diagnostics and monitoring treatment efficacy.
April 24, 2024
3 Articles